Related references
Note: Only part of the references are listed.Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort
Thomas Bettuzzi et al.
ACTA DERMATO-VENEREOLOGICA (2022)
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen et al.
ARTHRITIS CARE & RESEARCH (2022)
Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database
Laura Pina Vegas et al.
RHEUMATOLOGY (2021)
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
Jean-Guillaume Letarouilly et al.
RHEUMATOLOGY (2021)
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
Ulf Lindstrom et al.
RHEUMATOLOGY (2021)
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Ulf Lindstrom et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice
Jose A. Pinto Tasende et al.
REUMATOLOGIA CLINICA (2021)
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Roberta Ramonda et al.
RMD OPEN (2021)
Treatment persistence of biologics among patients with psoriatic arthritis
Amir Haddad et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Long-term remission and biologic persistence rates: 12-year real-world data
Kieran Murray et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA
Cecilie Heegaard Brahe et al.
RHEUMATOLOGY (2020)
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Maria Sole Chimenti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Rosa Parisi et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2019)
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
Florenzo Iannone et al.
CLINICAL RHEUMATOLOGY (2018)
Adherence and resource use among psoriasis patients treated with biologics
Joseph S. Aleshaki et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2018)
Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health
Tania Gudu et al.
JOURNAL OF RHEUMATOLOGY (2017)
Biologic drug survival in Israeli psoriasis patients
Guy Shalom et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Value of a national administrative database to guide public decisions: From the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France
P. Tuppin et al.
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE (2017)
Switching biologics in the treatment of psoriatic arthritis
Joseph F. Merola et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality
Aurelie Bannay et al.
MEDICAL CARE (2016)
Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls
Juul M. P. A. van den Reek et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
French health insurance databases: What interest for medical research
G. Moulis et al.
REVUE DE MEDECINE INTERNE (2015)
The Epidemiology of Psoriatic Arthritis
Alexis Ogdie et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Balancing Automated Procedures for Confounding Control with Background Knowledge
Richard Wyss et al.
EPIDEMIOLOGY (2014)
Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2014)
Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry
Bente Glintborg et al.
ARTHRITIS AND RHEUMATISM (2013)
Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy
Gregorio Carretero
ARCHIVES OF DERMATOLOGY (2012)
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
A. Neumann et al.
DIABETOLOGIA (2012)
Treatment Response, Drug Survival, and Predictors Thereof in 764 Patients With Psoriatic Arthritis Treated With Anti-Tumor Necrosis Factor α Therapy Results From the Nationwide Danish DANBIO Registry
Bente Glintborg et al.
ARTHRITIS AND RHEUMATISM (2011)
Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals
Stanley Xu et al.
VALUE IN HEALTH (2010)
Ecological association between a deprivation index and mortality in France over the period 1997-2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death
Gregoire Rey et al.
BMC PUBLIC HEALTH (2009)
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Amr A. Saad et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Evaluating medication effects outside of clinical trials: New-user designs
WA Ray
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Share Paper
